This listing of claims will replace all prior versions, and listings, of claims in the application:

Amendments To The Claims:

Claims 1-27 (cancelled).

28. (Previously presented) A composition comprising an isolated antibody capable of binding to an epitope of the protein encoded by SEQ ID NO: 16, wherein said antibody has anti-tumorigenic activity.

29. (Previously presented) A composition according to claim 28, wherein said antibody inhibits the growth of tumorigenic cells by at least about 50%.

30. (Previously presented) A composition according to claim 28, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

E1

31. (Previously presented) A composition according to claim 28, wherein said antibody is selected from a group consisting of anti-K19T, anti-S14R, anti-E19V, and anti-A14R antibodies.

32. (Previously presented) A composition according to claim 28, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 3.

33. (Previously presented) A composition according to claim 28, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 4.

34. (Previously presented) A composition according to claim 28, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 5.

35. (Previously presented) A composition according to claim 28, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 6.

36. (Previously presented) A composition according to claim 28, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 7.

37. (Previously presented) A composition according to claim 28, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 16.

38. (Previously presented) The composition of claim 28, wherein said antibody is a chimeric antibody comprising a plurality of portions, wherein at least one portion is derived from a human.

39. (Previously presented) The composition of claim 38, wherein at least one portion is derived from a non-human animal.

E1

40. (Previously presented) The composition of claim 39, wherein said non-human animal is a mouse.

41. (Previously presented) The composition of claim 38, wherein said at least one portion is a constant region.

42. (Previously presented) The composition of claim 38, wherein said at least one portion is a variable region.

43. (Previously presented) The composition of claim 28, further comprising a cytotoxic molecule, wherein said antibody is attached to said cytotoxic molecule.

44. (Previously presented) The composition of claim 43, wherein said cytotoxic molecule is selected from the group consisting of toxins, oncotoxins, mitotoxins, immunotoxins, and antisense oligonucleotides.

45. (Previously presented) The composition of claim 43, wherein said cytotoxic molecule is an oncotoxin.

46. (Previously presented) A composition comprising a monoclonal antibody capable of binding to an epitope of the protein encoded by SEQ ID NO: 16, wherein said monoclonal antibody has anti-tumorigenic activity.

47. (Previously presented) A composition according to claim 46, wherein said antibody inhibits the growth of tumorigenic cells by at least about 50%.

48. (Previously presented) A composition according to claim 46, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

E1

49. (Previously presented) A composition according to claim 46, wherein said antibody is selected from a group consisting of anti-K19T, anti-S14R, anti-E19V, and anti-A14R antibodies.

Claims 50-55 (Cancelled).

56. (Previously presented) A method of inhibiting tumorigenic activity, comprising obtaining an antibody capable of binding to an epitope of the protein encoded by SEQ ID NO: 16, wherein said antibody inhibits tumorigenic activity; and contacting said antibody with the protein encoded by SEQ ID NO: 16.

57. (Previously presented) A method according to claim 56, wherein said antibody is selected from the group consisting of anti-K19T, anti-S14R, anti-E19V, and anti-A14R antibodies.

58. (Previously presented) A method according to claim 56, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

59. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 3.

60. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 4.

61. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 5.

62. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 6.

63. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 7.

E1

64. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 16.

65. (Previously presented) A method of inhibiting tumor cell proliferation, comprising administering to a tumor cell an effective amount of an antibody capable of binding to an epitope encoded by SEQ ID NO: 16, wherein said antibody inhibits tumor cell proliferation.

66. (Previously presented) A method according to claim 65, wherein said tumor cell is selected from the group consisting of breast, ovarian, adipose, brain, liver, and kidney cells.

67. (Previously presented) A method according to claim 65, wherein said antibody inhibits tumor cell proliferation by at least about 50%.

68. (Previously presented) A method according to claim 65, wherein said antibody is selected from the group consisting of anti-K19T, anti-S14R, anti-E19V and anti-A14R antibodies.

69. (Previously presented) A method according to claim 65, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

70. (Previously presented) A method according to claim 65, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 3.

71. (Previously presented) A method according to claim 65, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 4.

E1

72. (Previously presented) A method according to claim 65, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 5.

73. (Previously presented) A method according to claim 65, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 6.

74. (Previously presented) A method according to claim 65, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 7.

75. (Previously presented) A method according to claim 65, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 16.